cardiology
Research

Victorians reveal secret of SGLT2 cardiac benefits

Cardiac imaging has shed light on the possible mechanism behind the reduction in cardiovascular death and heart failure seen with an SGLT-2 inhibitor. Associate Professor Neale Cohen and colleagues from the Baker Heart and Diabetes Institute, Victoria have shown that the use of empagliflozin in patients with type 2 diabetes is associated with a reduction ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic